The international surgical journal with global reach

This is the Scientific Surgery Archive, which contains all randomized clinical trials in surgery that have been identified by searching the top 50 English language medical journal issues since January 1998. Compiled by Jonothan J. Earnshaw, former Editor-in-Chief, BJS

Six versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. Lancet 2019; 393: 2599–2612.

Published: 2nd September 2019

Authors: Earl HM, Hiller L, Vallier A-L, Loi S, McAdam K, Hughes-Davies L et al.

Conclusion

There was no advantage for one year compared to six months of trastuzumab in this study that included over four thousand women: after median 5.4 years, disease-free survival was 89.4 versus 89.8 per cent, respectively.

Pubmed Link